探索Boswellia serrata三烯:白血病抑制因子受体调节的新前沿
Claudia Finamore1, Carmen Festa1, Mattia Cammarota1
1Department of Pharmacy, University of Naples "Federico II", Via D. Montesano, 49, Naples 80131, Italy.
ACS omega
|June 9, 2025
概括
Boswellia serrata提取物抑制白血病抑制因子 (LIF) 和其受体 (LIFR) 相互作用,显示出治疗肝纤维化的潜力. 阿尔法-博斯韦利克酸被确定为向LIFR的关键化合物.
科学领域:
- 植物化学 植物化学
- 分子药理学分子药理学
- 肝病学 肝病学是一种肝病学.
背景情况:
- 印度香 (Boswellia serrata) 具有抗炎和抗癌的功效.
- 它在肝纤维化和癌症发展中的治疗潜力在很大程度上仍未被探索.
- 白血病抑制因子 (LIF) 和其受体 (LIFR) 系统与肝纤维化和癌症有关.
研究的目的:
- 调查 Boswellia serrata n-hexane 提取物对新目标的作用,特别是 LIF/LIFR 相互作用.
- 确定负责对抗LIF/LIFR系统的特定Boswellia组件.
- 探索 Boswellia 在肝纤维化中的治疗潜力.
主要方法:
- 使用高分辨率质谱和分子网络的非定向代谢学分析.
- 隔离和NMR光谱检测Boswellia三类代谢物.
- 使用LX-2细胞的体外测定和计算研究来分析分子相互作用.
主要成果:
- Boswellia serrata 的 n-hexane 提取物对 LIF/LIFR 相互作用表现出显著的对抗性活性.
- 几种博斯韦利克酸及其衍生物被确定为关键活性代谢物.
- 阿尔法-博斯韦利克酸被证实是LIFR抗剂,减少LX-2细胞中的原蛋白和α-SMA表达.
- 计算研究揭示了碳酸基在与人类LIFR (hLIFR) 部位结合中的关键作用.
结论:
- Boswellia serrata含有可以抑制LIF/LIFR通路的化合物,这表明肝纤维化的新疗法策略.
- 阿尔法-博斯韦利克酸是通过LIFR抗作用开发向肝纤维化治疗的有希望的候选药物.
- 这项研究为在肝脏疾病管理中利用博斯韦利亚衍生化合物开辟了新的途径.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K


